Kymera Therapeutics, Inc. KYMR R2KR3KPHARMA
Company Overview
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Why Investors Should Care
Revenue has grown at a 54.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.05.
Recent Developments
- Dec 2025 Revenue of $39.21M (-16.7% YoY); net profit $-311.35M.
- Trailing 12 Months Year-on-year growth — revenue +466.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 54.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 54.05% |
| 1 Year: | 466.40% |
Stock Price Performance
| 1 Year: | +188.22% |
| 6 Months: | +40.60% |
| 3 Months: | +58.36% |
| 1 Month: | +10.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.78 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 54.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KYMR Kymera Therapeutics, Inc. R2KR3KPHARMA | 117.39 | -36.23 | $9.76B | 0.00% | -21.05% | -24.15% | 54.05% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 950.00K | 3.43M | 3.29M | 14.53M | 18.70M | 18.52M | 20.34M | 9.62M | 11.51M | 9.55M | 9.47M | 16.51M | 4.73M | 10.29M | 25.65M | 3.74M | 22.10M | 11.48M | 2.76M | 34.37M | 65.00M |
| Operating Income | -11.86M | -11.25M | -14.19M | -8.08M | -13.17M | -24.73M | -28.64M | -36.93M | -40.81M | -44.88M | -45.33M | -43.38M | -57.51M | -57.83M | -50.92M | -72.12M | -74.43M | -84.56M | -92.52M | -84.15M | -75.61M |
| Net Income | -11.42M | -10.93M | -13.99M | -7.99M | -13.07M | -24.66M | -28.58M | -36.68M | -40.26M | -43.00M | -40.93M | -38.80M | -52.87M | -48.56M | -42.06M | -62.49M | -65.58M | -76.61M | -82.17M | -69.23M | -61.21M |
| Diluted EPS | - | - | - | - | - | -0.55 | -0.56 | -0.71 | -0.78 | -0.79 | -0.70 | -0.67 | -0.90 | -0.69 | -0.58 | -0.82 | -0.82 | -0.95 | -0.94 | -0.71 | -0.62 |
| R&D Expense | 11.31M | 12.12M | 13.82M | 15.78M | 25.96M | 35.22M | 38.31M | 35.94M | 41.29M | 43.88M | 42.23M | 45.77M | 48.12M | 48.82M | 59.20M | 60.41M | 80.25M | 78.39M | 74.09M | 98.16M | 119.48M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.93M | 34.03M | 72.83M | 46.83M | 78.59M | 47.07M | 39.21M |
| Operating Income | -42.20M | -46.30M | -100.53M | -161.26M | -165.53M | -261.63M | -349.40M |
| Net Income | -41.25M | -45.59M | -100.22M | -154.81M | -146.96M | -223.86M | -311.35M |
| Diluted EPS | - | -3.15 | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 |
| R&D Expense | 37.16M | 62.10M | 137.02M | 164.25M | 189.08M | 240.25M | 316.57M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 116.70M | 487.18M | 605.90M | 603.13M | 575.76M | 978.03M | 1.74B |
| Total Equity | -34.44M | -74.41M | 283.89M | 459.64M | 490.15M | 394.97M | 835.62M | 1.58B |
| Cash & Equivalents | - | 76.02M | 31.00M | 47.98M | 68.39M | 109.97M | 120.26M | 357.01M |
| Total Liabilities | - | 82.03M | 203.29M | 146.27M | 112.98M | 180.79M | 142.42M | 163.15M |
| Current Liabilities | - | 34.57M | 110.62M | 92.54M | 71.34M | 85.69M | 67.77M | 83.21M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 17.91M | 88.13M | -128.95M | -153.09M | -102.83M | -194.50M | -232.89M |
| Investing Cash Flow | -16.49M | -422.59M | -99.83M | 20.52M | 139.89M | -404.08M | -521.06M |
| Financing Cash Flow | 34.91M | 289.26M | 250.28M | 153.00M | 4.19M | 608.85M | 990.71M |
| Capital Expenditure | -532.00K | -9.10M | -1.60M | -2.84M | -34.48M | -12.84M | -1.45M |
| Free Cash Flow | 17.37M | 79.03M | -130.54M | -155.92M | -137.31M | -207.34M | -234.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -1,438.5% | -136.1% | -138.0% | -344.4% | -210.6% | -555.8% | -891.1% |
| Net Margin % | -1,405.8% | -134.0% | -137.6% | -330.6% | -187.0% | -475.6% | -794.0% |
| ROE % | 55.4% | -16.1% | -21.8% | -31.6% | -37.2% | -26.8% | -19.7% |
| ROCE % | -51.4% | -12.3% | -19.6% | -30.3% | -33.8% | -28.7% | -21.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.85% | 12.35M | $1.46B |
| 2 | Baker Bros. Advisors, LP | 10.41% | 8.66M | $1.02B |
| 3 | Avoro Capital Advisors LLC | 8.99% | 7.47M | $883.14M |
| 4 | Price (T.Rowe) Associates Inc | 8.55% | 7.11M | $840.40M |
| 5 | T. Rowe Price Investment Management, Inc. | 7.53% | 6.26M | $739.30M |
| 6 | Blackrock Inc. | 6.66% | 5.54M | $654.34M |
| 7 | BVF Inc. | 4.66% | 3.87M | $457.48M |
| 8 | Wellington Management Group, LLP | 4.42% | 3.68M | $434.20M |
| 9 | Vanguard Portfolio Management LLC | 3.60% | 2.99M | $353.53M |
| 10 | Siren, L.L.C. | 3.53% | 2.94M | $346.87M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KYMR
KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQR2MybFJnaml4NnFQd0lYSUU0VTRJSWs2RFNweFBkbVZjRzJvOTZicFZROWNTLVR1WDBhY3JmeWNvOHo5SHAzUVFxZG0tTmhBLXVwODFBZ1h3RlZCQVlkMVFhWTRrMzJ3ckxzdjZ0UW5tMXEzS3hEUl9jQU1mN3E3am0xOWVLQ21SelZCOT…
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOX0dEZmt2NjZ5M0s1WWQ5cjh4QWpRRlQ3VHpqbzZZWUtZV2VkSmYtaTNXYkd6WTdBdy1oQWhYTWFYaDZoMkxRemd2NS1RN0ZYWHJ3YmQ4bmlLYnd1RHM2VzI2dTBNbWQ3ck9VbldjT2tfczJmN2JoQVdQR2pycjFsalpYb09tTmhMb1IyeW…
36,237 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by Legal & General Group Plc - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQWnN4TFk0WnpLbWJYMzk0S1BqVGpyc1J3OEdJUnp3WWpZTFNZTHFkSlVQNHRrLXFjWTVSajd3UTJPRnEyZFhiTXlhQWg4bnZvOGRWcUl1dXU3a0RPN2V6V2hZcmxxR0dGZVYtcmpsUDFTSVczM0RPSmZwNDRLb2s0ZkhFRDU4UnI4ZzlwV3…
Five September events will webcast Kymera live - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPb3FJaXNZMmdpbnBoQ25jRVpiZl9QRE0wZHk5TXZaVUlyWUdodHYxeEJyMkhZTWFZa0QzcXhFSkZ4TWZVbkx6X1lLZzB2RDFib3NsWmZqVmx6TEdmb2VvaEl3NWZWTEYwbmZtSm5lSl92RndIeFFpby12V191ZDlvMEl5eW4yeXRzd1dRTW…
Have Kymera Therapeutics Insiders Been Selling Stock? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxOYWlZR1kzQjUxaDZicHRFUmtlLXY3VWszRWdGZkp2VEMzWV9McEJrT09HYS1DMjVELW1Kc1drRnphTDBIRWhpZXp6VFcyZVdHdEU1S09RbjZMVXRZUnVvZDlxSklyQjVaRWNaMEw4dnI4aEhzeVU0ejNqODJEczFrUXFMU1lqcDFHNU9uSk…
Kymera Therapeutics chief legal officer Adams disposes of $744k in KYMR stock - Investing.com Canada
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQVG9oM3RTMUpzNFZ1WmMzNnBGVVBCM1dCc3V6YlVmYjdFeVVIUzYyRktMUUdCTlFKcFlLQV9UR1l1Q0hiMmd4TFVrV1hQaWxIczNCM0xVVzBCVWRLcU5wTmJyRXZ1VEVNZXNhY2FudUVhVXBMUVVFT1EweVRxWVRCd3gyTE1IVE5FMU55Qn…
KYMR — Frequently Asked Questions
What is the current share price of Kymera Therapeutics, Inc. (KYMR)?
As of 2026-09-07 16:24 PDT, Kymera Therapeutics, Inc. (KYMR) trades at $117.39 on NasdaqGM. Its 52-week range is $40.69 to $127.31.
What is the market capitalisation of KYMR?
Kymera Therapeutics, Inc. (KYMR) has a market capitalisation of $9.76B on NasdaqGM.
What is the P/E ratio of KYMR?
KYMR trades at a trailing price-to-earnings (P/E) ratio of -36.23. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.74.
What is the return on equity (ROE) of KYMR?
KYMR has a return on equity (ROE) of -24.15%. Its return on capital employed (ROCE) is -21.05%.
Is KYMR a good stock to buy?
This page provides a data-driven analysis of Kymera Therapeutics, Inc. (KYMR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.